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ABSTRACT The 29-residue peptide hormone glucagon forms amyloid ﬁbrils within a few hours at low pH. In this study, we
use glucagon as a model system to investigate ﬁbril formation by liquid-state 1H-NMR spectroscopy One-dimensional,
correlation, and diffusion experiments monitoring the ﬁbril formation process provide insight into the early stages of the pathway
on which the molecules aggregate to ﬁbrils. In conjunction with these techniques, exchange experiments give information about
the end-state conformation. Within the limits of detection, there are no signs of larger oligomeric intermediates in the course of
the ﬁbril formation process. Kinetic information is extracted from the time course of the residual free glucagon signal decay. This
suggests that glucagon amyloids form by a nucleated growth mechanism in which trimers (rather than monomers) of glucagon
interact directly with the growing ﬁbrils rather than with each other. The results of proton/deuterium exchange experiments on
mature ﬁbrils with subsequent dissolution show that the N-terminal of glucagon is the least amenable to exchange, which
indicates that this part is strongly involved in the intermolecular bonds of the ﬁbrils.
INTRODUCTION
The spontaneous aggregation of polypeptides into macro-
molecular amyloid fibrillar structures has received much
attention in recent years (1–3). Amyloidosis is involved in
more than 20 major diseases and is associated with neuro-
degeneration and systemic malfunctions, the most well-
known of which include Alzheimer’s disease, Parkinson’s
disease, type II diabetes mellitus, Huntington’s disease, and
the various prion diseases (1,2,4,5). It has been suggested that
essentially all polypeptides can form amyloid-like aggregates,
given the right circumstances (6). In addition to the direct
detrimental disease effects, fibril formation also can be prob-
lematic in industrial applications that use polypeptides as
pharmaceuticals. It is a major concern to keep the therapeutics
in a stable, native form, because disruption to a nonnative
conformation might trigger aggregation/fibril formation, with
consequences including diminished activity, wrong dose mea-
sures, and potential cytotoxic effects from the fibrils through
the activation of apoptotic signaling pathways (7).
Substantial efforts have been devoted to the study of the
kinetics of amyloid formation and amyloid structures to un-
derstand the basic mechanism of fibril formation and to
prevent or reverse the process. Kinetic studies have exploited
amyloid interactions with dyes such as Congo red, fluores-
cence measurements of interactions with thioflavin T, and
dynamic light scattering (8–11). Secondary structure mea-
surements have involved spectroscopic methods such as
circular dichroism and Fourier transform infrared (12–14),
whereas structures with different degrees of resolution have
been established using electron microscopy (15), atomic
force microscopy (AFM) (16), x-ray fiber diffraction (17),
x-ray microcrystallography (18), small-angle x-ray scattering
(19), and solid-state NMR spectroscopy (20–24). These
studies reveal diverse fibrillar super-structures, most of which
are based on a so-called cross-b-structure (25) now com-
monly associated with the definition of amyloids (1,2). Due
to the complexity of the system—with intermediate states,
highly varying dynamics, molecular interactions, rapid change
of the particles from individual molecules in solution to large
solid aggregate structures, and the potential to form fibrils
with different morphology under different conditions—we
are still far from atomic resolution structural insight into the
full process of fibril formation. Although intensely studied,
only little is known about the early stages of fibril formation,
the associated folding/refolding processes, the clear influence
from environmental parameters (pH, ionic strength, con-
centration, temperature, etc.), the dependence on seeds, the
formation of intermediate oligomers, protofibrils, exchange
of molecules with the fibrils, and variations in initiation and
lag time, and much more (14,26–30). The proposed generic
ability of proteins to form cross-b structures suggests that
backbone interactions are very prominent in fibril structures.
Side-chain interactions nevertheless still contribute to con-
tacts between the strands (18) and significantly modulate the
kinetics of aggregation (31). An expected common feature is
the aggregation of monomers to an oligomeric intermediate,
which may either form the basis for further aggregation or be
a ‘‘dead-end’’ structure (32–35). These oligomers are cur-
rently subject to intense scrutiny, because there is growing
evidence that they are the cytotoxic species, possibly due to
membrane-perturbing abilities, whereas the fibrils may rep-
resent an inert storage state (1,2).
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With the aim of exposing features of the early stages of
fibril formation, this study uses liquid-state 1H-NMR spec-
troscopy to address fibril formation of glucagon—a 29-resi-
due peptide hormone that has been used as a model system
for the formation of amyloids with methods such as thioflavin
T fluorescence (14), electron microscopy (30), AFM (36,37),
Fourier transform infrared, and circular dichroism spectros-
copy (38), and, recently, microcrystal microbalance (35).
Cytotoxic effects also have been reported for glucagon fibrils
(39). Glucagon (primary sequence: HSQGT FTSDY
SKYLD SRRAQ DFVQW LMNT) is critical in the balanc-
ing of the blood glucose level. As the antagonist to insulin,
glucagon induces the conversion of glycogen to free glucose
(40,41), and it has been used pharmaceutically as a medica-
ment against hypoglycemia, for example (42). Glucagon is
known to form fibrous b-sheet structures under various
conditions (14,17,36,37,43,44). The structure of crystallized
glucagon has been determined with x-ray diffraction (45),
revealing a largely a-helical trimer held together by hydro-
phobic interactions. In solution and bound to dodecyl phos-
phocholine (DPC) micelles, the structure of glucagon has
been studied by liquid-state NMR (46–48). These studies
also reveal an a-helical structure that is only well-defined,
however, in a short region toward the C-terminus. Liquid-
state NMR (48) and light scattering (30) studies suggest
equilibrium in the solution between the monomeric and tri-
meric states, with the trimer favored at higher glucagon
concentrations. It is still an open question, however, how
these structures are linked to the formation of fibrils.
MATERIALS AND METHODS
Glucagon
Purified wild-type human glucagon of pharmaceutical grade quality
(.98.9% pure, produced by fermentation) was kindly provided by Novo
Nordisk A/S (Bagsværd, Denmark). It was dissolved in H2O with 5% D2O
(with 100% D2O for diffusion ordered spectroscopy (DOSY) experiments,),
0.1 mM NaN3, and adjusted to pH 2.0 with 1 M HCl. The peptide concen-
tration was either 1.4, 3.5, or 7.0 mg/mL (0.4, 1.0, or 2.0 mM). For the
exchange experiments, the buffer was prepared in the same way with D2O
instead of H2O. The DMSO (dimethyl sulfoxide) buffer consisted of 95%
DMSO-d6, 5% D2O (deuterated sample)/H2O (reference), and the pD*/pH
was adjusted to 5.0 with HCl/DCl (49).
Glucagon ﬁbrils
Fibrils were produced by solubilizing 4.0 mg glucagon in 600mLH2O buffer
at pH 2 and adding 6 mL 30 mM Na2SO4. For exchange experiments, the
solution was left at room temperature for 4 days, after which it had become a
gel. Fibrils were dried by flash-freezing and freeze-drying.
NMR spectroscopy
NMR experiments were performed with spectrometers operating at 1H Lar-
mor frequencies of 400 or 700 MHz (Bruker Avance 400 and Avance II 700,
respectively; Bruker Biospin, Rheinstetten, Germany) and 800-MHz spec-
trometers (Varian Inova; Varian, Palo Alto, CA) equipped with a double-
resonance or a triple-resonance z-gradient room temperature (for 400 and
700 MHz), or a cryogenic probe (for 800 MHz). In all experiments, the
temperature was controlled to 298.3 K. To monitor fibril formation, the fol-
lowing series of experiments were conducted while the sample was aging. 1),
A series of nuclear Overhauser enhancement spectroscopy (NOESY) experi-
ments with 200-ms mixing time (700 MHz, 8 transients, 600 increments, ex-
perimental time 4 h 15 min each). Control one-dimensional (1D) spectra were
acquired in between the NOESY spectra. 2), A series of total correlation spec-
troscopy (TOCSY) experiments with 40-ms mixing time and the same ac-
quisition parameters as the NOESY series. 3), A series of stimulated-echo
bipolar gradient diffusion DOSY (50) experiments with 4-ms encoding gra-
dients and 100-ms diffusion delay (400 MHz, 32 transients, 32 gradient in-
crements, experimental time 1 h each). Another DOSY series was sampled
with 4.5-ms encoding gradients and 1200-ms diffusion delay to search for
potential slower decays stemming from large size molecules (400 MHz, 64
transients, 16 increments, 1 h, data not shown).Dioxane (3.8mM)was used as
a reference to verify that the diffusion coefficientwas not affected by changing
solvent properties or the change in concentration. 4), For secondary structure
parameters, additional spectra were acquired on fresh samples of 1.4 and 7.0
mg/mL concentrations (while verifying that the sample was still in its lag
phase), i.e., aNOESY (800MHz, 1600 increments, 200-msmixing time)with
20 transients for 1.4 mg/mL and 8 transients for 7.0 mg/mL, and two TOCSY
(800 MHz, 4 transients, 1600 increments, 25- and 70-ms mixing time).
Principal component analysis
Principal component analysis (PCA) (51) reduces the dimensionality of a
data set (e.g., the number of spectra) by describing correlated variations. It
essentially groups features of the spectra that behave the same way under
changing conditions, e.g., time. Each component is given by a group of
features (positive and/or negative changes) called the ‘‘loading’’ and a score
plot, which describes how much of the component is present under the dif-
ferent conditions. Ideally the sum of all the scores 3 loadings describes the
noise-free part of the data set. PCA was conducted on a data set obtained
from a series of 1D spectra divided into 0.01 ppm regions (bins) over which
the signal was integrated to obtain the signal intensity. The region around the
residual water signal (6.0–4.0 ppm) was removed to not compromise the
analysis. The data were scaled to obtain unit variance (i.e., each region/bin
was divided by the standard deviation of the integral of that region within the
entire data set) and then centered. This scaling reduces the weight of sto-
chastic large amplitude variations and increases the weight of small corre-
lated changes. Singular value decomposition was performed on the matrix X
containing the scaled binned spectra, resulting in three matricesU, D, and V,
where U 3 D 3 V ¼ X. The scores are contained in U 3 D; V contains the
loadings, and D contains the contribution from each component. The re-
sulting scores and loadings were then rescaled to the original intensities (i.e.,
each region/bin of the loadings was multiplied by the standard deviation of
the integral of that regionwithin the entire data set, and the scores were scaled
so that U3 D3 V ¼ X still applies). The PCA and pre- and postprocessing
was performed using inhouse R-scripts (the R project) (52).
H/D exchange
A total of 600 mL deuterated buffer (pD* 2.0) was added to the freeze-dried
fibrils and placed on a shaker for the exchange period of 24 h. After this
period, exchangeable protons on the outside of the fibril should be exchanged
with deuterium, whereas the core should still contain protons. A reference
sample was treated in the same way but exchanged in H2O buffer rather than
D2O buffer. The exchange period was terminated by flash-freezing and
freeze-drying the fibrils. The fibrils were dissolved in 98% trifluoroacetic
acid-d (53), flash-freezed and freeze-dried. Then, the sample was resolubi-
lized in DMSO buffer at pD* (deuterated sample)/pH (reference) 5.0, a value
at which exchange with the DMSO is minimized (49). The dissolving with
trifluoroacetic acid was fast, ;5 min, which was essential to avoid a further
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exchange in the dissolving medium. Dissolving with 40% trifluoroethanol-
d3 and 95% DMSO-d6 (54) also was attempted (data not shown); this pro-
cess, however, was too slow and was observed decreasing the signal of the
reference sample significantly. Exchange rates were calculated on the basis
of TOCSY spectra with 30-ms mixing time (400 MHz, 8 transients, 600
increments, experimental time 3 h 30 min each).
AFM
A 7.0 mg/mL solution of glucagon was left to change to a viscous gel-like
phase. A very small scoop of this gel-like phase was taken with a pipette tip
and resuspended in 100 mL deionized water. A total of 2–5 mL drops of the
resuspended sample were placed on freshly cleaved mica, and the drop
was gently dried with nitrogen. Imaging was performed with a microscope
(PicoSPM; Molecular Imaging, Phoenix, AZ) in contact mode using a
10-mm scanner.
RESULTS AND DISCUSSION
Time evolution of ﬁbril formation
After the preparation of a 3.5 mg/mL solution of glucagon,
the consistency of the sample changes within a period of
typically 1–2 days from a clear solution toward a viscous gel
phase containing spherulites in the micrometer-size range
(Fig. 1 A). The time before fibril formation was not well re-
producible. Sometimes the process takes much longer; in
other cases, it starts immediately after preparation of the
sample. An extract of the gel was investigated by AFM. Fig.
1 B shows the typical mesh of fibril structures in the repre-
sentation of the deflection derivative. The typical thickness of
the fibrils is 30–70 nm, which is in accordance with the
values previously reported by Dong et al. (37)
During the time course of fibril formation, 1H liquid-state
NMR spectra display significant changes (Fig. 2 A). The
upper spectrum represents the initial stage, whereas the lower
spectrum was observed after 35 h when advanced fibril for-
mation was macroscopically visible, as shown in Fig. 1 A.
Upon fibril formation, all peaks decreased in intensity. In our
interpretation, it should be kept in mind that only monomers
and oligomers up to a range of 200 kDa (;60 glucagon
molecules) will give detectable signals in current liquid-state
NMR experiments. The signals of slowly tumbling larger
aggregates, such as protofibrils and fibrils, are broadened
beyond detection. The time series of spectra is supposed to
monitor the pathway toward the unobservable state. For all
peaks, we observed a systematic decrease of the signal in-
tensity over time. This development manifested visually
through a decrease of the peak heights, because no line
broadening was seen for the observable signals throughout
fibril formation. Many of the signals, however, narrowed in
the course of fibril formation, an effect that will be discussed
below. The absence of line broadening suggests that the de-
cay of the signal represents a loss of free glucagon monomers
(or very small oligomers) rather than an increase in size of
small polymeric units. The spectra revealed no signs of ad-
ditional signals that could come from low molecular weight
intermediate states.
The decay of the 1D 1H liquid-state NMR signal intensities
occurs after a lag time of between 0 and 100 h in a ramp phase
of fast decay, which ends in a smooth asymptote to zero. The
length of the ramp phase is relatively reproducible in 8 h. In
Fig. 3 A, the behavior is demonstrated for the well-resolved
and representative singlet of the His-1 e1 proton (8.59 ppm)
and for the Ala-19 Hb signal (1.31 ppm). The sigmoidal
overall decay profile for the integrated signal intensity is
comparable to analogous observations by means of thioflavin
T fluorescence (14,30), and it provides information about the
process of aggregation. For example, it is not consistent with
a model in which each collision of two free glucagon mole-
cules leads to aggregation with a certain probability, because
such a scenario would lead to an exponential rather than a
sigmoidal decay of the signal. We interpret this particular
shape in terms of a model in which the fibril-forming species
binds predominantly to existing aggregates and aggregates
fragment with a certain probability (55,56).
The velocity of fibril formation, measured as the loss of the
peak intensity I, is in this model:
v ¼ dI
dt
} ½s  ½a; (1)
where [s] is the concentration of the fibril-forming species
and [a] is the concentration of aggregates. Due to the lack of
aggregates, the rate is initially very slow (lag phase). When a
FIGURE 1 (A) Optical microscope (203) and (B) AFM
images of a glucagon sample after fibril formation.
368 Svane et al.
Biophysical Journal 95(1) 366–377
significant number of aggregates has been formed, the
velocity of fibril formation increases (ramp phase), until the
formation of fibrils is limited by the decreasing availability of
the fibrillating species. The aggregate concentration [a] is
proportional to the loss of free glucagon, as in the following:
½a ¼ gð½f 0  ½f Þ; (2)
where [f] is the total concentration of free glucagon, [f]0 is the
starting concentration of free glucagon, and 1/g is determined
by the average size of the fibrils. The size is determined by the
probability of fragmentation. Because the signal intensity I
reflects the concentration of free molecules, one can set up the
following:
d½f 
dt
¼ r½sð½f 0  ½f Þ; (3)
where g is merged with the proportionality factor for the
collision probability to r. If all species of free glucagon can
associate with the fibril, i.e., [s] ¼ [f], Eq. 3 is formally equal
to the logistic equation, except for the negative proportion-
ality:
½f ðtÞ ¼ ½f 0
11 ert
: (4)
The origin of the time axis is shifted by the lag phase plus half
of the ramp phase l to the origin of the point of symmetry of
the sigmoid t ¼ t  l; which allows us to circumvent the
problem of an ill-defined initial condition. If [a](t ¼ 0) was
zero, fibril formation would never start. The problem of the
starting concentrations is related to the poor reproducibility
of the lag phase. For the same reason, the use of preformed
fibrils as seeds decreases the lag time (30). On fitting Eq. 4 to
the signal intensity of the His-1 e1 and Ala-19 b protons, we
find l¼ 17.5 h and r¼ 0.17M1s1 (Fig. 3 B). The deviation
from the model during the lag phase may be explained by an
instability in the measurements. Due to the change of the
FIGURE 2 Excerpts from series of 1D 1H liquid-
state NMR spectra of glucagon monitored during
fibril formation. (A) Amide (8.6–7.7 ppm) and
aromatic/amino region (7.5–6.3 ppm) from 0 to 35 h
in steps of 75 min after sample preparation (from
back to front). The frequency axis refers only to the
first (upper) spectrum at 0 h; the subsequent spectra
contain offsets in both dimensions to enhance vis-
ibility. (B–D) Excerpts exploring spectral changes
for the peaks of Ser-2 and Gln-3 (B), His-1 e1 (C),
and the upfield part (D) of the amide region during
the ramp phase. (A) The spectra was recorded at
400 MHz using a 3.5-mg/mL sample of glucagon.
(B–D) The spectra in were reproduced at 700 MHz
using a 7.0-mg/mL sample.
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sample phase during the experiment, an automatic correction
of field homogeneity was necessary, which was not perfectly
stable at the beginning.
The discrepancy between model and experiment after the
end of the ramp phase, however, cannot be neglected. To
explore the origin of the relatively slow decay, we included
an equilibrium between fibril-bound and free glucagon by
including a backward rate constant b in Eq. 3, as shown in the
following:
d½f 
dt
¼ ðr½s  bÞð½f 0  ½f Þ: (5)
This model, however, does not trace the asymmetry correctly
(Fig. 3 C). Moreover, the experimental data do not convinc-
ingly exhibit an asymptotic approach to an equilibrium rather
than to zero.
This discrepancy reveals that a more complex model is
needed to explain the experimental observations, thereby
reinforcing the potential for obtaining a more detailed insight
into the early stages of fibril formation through simple 1D
NMR decay experiments. Motivated by earlier reports de-
scribing an equilibrium between monomer and trimer
(30,48), we introduced this possibility using:
K ¼ ½t½m3; (6)
where K is the trimer formation constant, and [m] and [t] are
the monomer and trimer concentrations, respectively. The
free glucagon concentration is:
½f  ¼ ½m1 3½t: (7)
The existence of a monomer-trimer equilibrium is supported
by line broadening and by diffusion experiments (Fig. 4). The
equilibrium constant K can be obtained from the concentra-
tion dependence of the chemical shift (48). Our data are
consistent with aK value of 60,000M2; this value, however,
contains a relatively high uncertainty.
The coexistence of a trimer population suggests the
question of whether this species lies on the pathway to fibril
formation or whether it is only a dead-end sideway caused by
high concentrations as is common for peptides. The possi-
bility that both species, monomer and trimer, contribute
FIGURE 3 (A) 1H liquid-state NMR signal
intensity of the His-1 e1 (open diamonds) and
Ala-19 b (solid diamonds) protons as a function
of time after dissolving the sample, and the
attempts to fit a logistic function to the Ala-19
Hb data without (B, line) (Eq. 4) and with (C,
line) (Eq. 5) a backward rate. (D) This shows the
fitting to the data of a model (line) (Eq. 9),
where the trimer is the only fibril-forming spe-
cies.
FIGURE 4 DOSY spectra of a 7.0-mg/mL solution of glucagon before
(solid contour lines) and toward the end of the ramp phase (dotted contour
lines). Relative intensities of the lowest contour level: before, 1.00; end of
ramp, 0.72.
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equally to fibril formation already is covered by [s] ¼ [f] in
Eq. 3, the solution of which left room for improvement.
Instead, we probed the two possibilities that either only the
monomeric state ([s]¼ [m] in Eq. 3) or only the trimeric state
([s]¼ [t]) allowedbinding to thefibril. To obtain an equation in
[f], [m] is substituted in the former case by the real solution of
the cubic equation derived from Eqs. 6 and 7,
½m31 1
3K
½m  1
3K
½ f  ¼ 0: (8)
In the latter case, [t] is substituted in advance according to Eq.
7. To facilitate a numeric integration, the lag phase problem
was handled by means of an adjustable starting aggregate
concentration, [a]0, rather than a time shift:
d½f 
dt
¼ rð½f   ½mÞ ½f 0  ½f 1
1
g
½a0
 
(9)
with [m] given by Eq. 8. The other fit parameter was the rate
constant r. The shift of the equilibrium due to the nonlinear
constant K makes the curve asymmetric. This asymmetry
matches well with the behavior of the experimental data
when assuming that the trimer is in the pathway. With
decreasing concentration of free glucagon molecules, the
equilibrium shifts toward the monomeric state, so that there
are only few trimers remaining that can lead to the attachment
of a glucagon molecule to a fibril (Fig. 3D). For this model, r
is found to be 21 M1s1. The model that assumes that only
monomers attach to fibrils provides a curve similar to the case
where [s]¼ [f], and it therefore has to be rejected. The finding
above does not necessarily mean that whole trimers bind to
fibrils, but that there is a binding of one or more glucagon
molecules upon the collision of trimers with fibrils.
As every model, this model has to be considered as a
simplification that nevertheless describes the main charac-
teristics well. Residual deviations can be due to a nonconstant
g (e.g., by higher-order aggregation as bundling of fibrils as
seen by AFM (37) and/or even the aggregation to macro-
structures visible by light microscopy as shown in Fig. 1 A).
The interpretation of the variations in the 1D 1H-NMR
spectra is supported by the DOSY (50) 1H-NMR spectra
shown in Fig. 4. The spectra belong to a series that is mon-
itoring the behavior throughout the formation of fibrils,
starting from a concentration of 7.0 mg/mL glucagon. One
spectrum is acquired before the ramp phase (Fig. 4, solid
contour lines) and the other toward the end of the ramp phase
(Fig. 4, dotted contour lines). All spectral components of the
latter spectrum belong to molecules moving with an average
diffusion coefficient of 1.5 6 0.2 3 1010 m2/s, which is a
value that corresponds to a monomer. This value differs
(although the difference is at the limit of the precision of the
method) from that of the initial spectrum, 1.2 3 1010 m2/s,
which reflects the presence of a larger amount of trimers in
the initial phase (25% of the signal intensity when assuming
K ¼ 60,000 M2). The full set of DOSY spectra (not shown)
shows a gradual increase in diffusion coefficients in the
course of the formation of fibrils, which is in agreement with
the decreasing trimer/monomer ratios at lower concentrations
of free glucagon. With this setup, the DOSY experiment
should be capable of identifying multimers up to ;50 ag-
gregated molecules. However, none of the spectra reveal any
separate signals corresponding to higher-molecular-weight
oligomers. The increasing diffusion coefficient and the con-
stant coefficient of the dioxane reference also indicate that the
free molecules are moving without restriction from the gel/
fibril matrix formed by the emerging glucagon fibrils.
A more detailed look at the 1D spectra in Fig. 2 reveals that
the various resonances throughout the spectrum behave dif-
ferently in terms of their linewidth. The linewidth of the His-1
e1
1H-resonance (Fig. 2 C) remains constant throughout the
experiment. This is also the case for all other signals stem-
ming from the six N-terminal residues as demonstrated for
Ser-2, Gln-3, and Thr-5 in Fig. 2, B and D, which shows
excerpts from 1H-spectra reproduced at 700 MHz (all spectra
in Fig. 2, B–D were performed at a concentration of 7.0 mg/
mL glucagon rather than 3.5 mg/mL and the lag time in this
case was very short). In agreement with the translational
motion properties measured above in the DOSY experi-
ments, the rotational molecular tumbling, and so the line-
width of these signals, appear not to be affected by the
viscosity of the solution. The signals assigned to the other
residues of glucagon display a more complex behavior. In
addition to the amide proton resonance of Thr-5, Fig. 2 D
shows the amide signals of several residues between number
12 and 29. Whereas the intensities of these signals also show
a sigmoidal decrease, their linewidths change significantly.
Directly after sample preparation, the signals of the bulk
residues are broad and overlapping, whereas they begin to
resolve after 13 h, corresponding to the middle of the ramp
phase. This finding may seem counterintuitive at first glance,
but it is consistent with the nucleated growth mechanism and
the existence of a monomer-trimer equilibrium. Arbitrary
aggregation would lead to a broadening of lines over time due
to growing size of the aggregates, whereas nucleated growth
mechanism does not lead to such a broadening. On the
contrary, the initial line broadening is due to exchange be-
tween monomers and trimers (48) and, as the concentration
of residual free glucagon drops due to adsorption, there is less
exchange. After 24 h, the spectrum is very similar to a
spectrum of a freshly prepared glucagon sample of low
concentration (#1.4 mg/mL).
This explanation implies that there is no exchange be-
tween monomers and fibrils or protofibrils on a timescale
that would lead to line broadening, i.e., the range of micro-
to milliseconds (in that case, line broadening would not be
strongest in the absence of fibrils, i.e., in a freshly prepared
sample). Narayanan and Reif (57) recently reported ex-
change between monomers and high mass oligomers for the
peptide Ab1–40 by means of saturation transfer difference
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(58), a finding that we could not reproduce for glucagon
(data not shown).
To facilitate discussion and description in the following sec-
tions,wewill use the term ‘‘freeglucagon’’ for the concentration-
dependent equilibrium state involving monomers and trimers.
To further evaluate the possibility of a buildup of minor
spectral components, such as those from larger oligomers at
low concentrations, we took advantage of PCA (51) for un-
biased evaluation of correlated spectral variation in large data
sets. Fig. 5 A presents the results from PCA of the 1D spectra
series in Fig. 2 A. PCA eliminates redundant information in
the data set and filters noise by describing the correlated
variation within the data set by a relatively small number of
loadings and scores instead of a large number of frequencies
and intensities. The loading for the first principal component
(PC1) describes the correlated spectral variation that explains
most of the variance in the data set. The associated scores
describe the amount of the loading present in each spectrum
relative to the mean spectrum. The second principal com-
ponent (PC2) describes the correlated spectral variation once
the variation explained by PC1 is removed, and so forth. PC1
accounts for 98.3% of the variance between the spectra
throughout fibril formation. The evolution of the score (Fig.
5 A) for PC1 with time basically describes the decrease in
peptide concentration during the fibril formation process as
shown in Figs. 2 and 3. The loadings of PC1 (Fig. 5 B) are
virtually identical to the spectrum for the initial state. PC2
explains 1.0%, which is most of the remaining variance. The
loading for PC2 (Fig. 5 C) includes both negative and posi-
tive signals, indicating peakmovement and/or changes in line
shape. This is consistent with the changes in the spectra as the
monomer-trimer equilibrium shifts with the decreasing con-
centration of free glucagon upon fibril formation (as shown in
the excerpts in Fig. 2, B and C. Note the contribution to PC2
from Ser-2, which moves as a function of time, and the neg-
ligible contribution from Gln-3, which does not move with
time. A weighted difference spectrum between NMR-visible
glucagon before and after fibril formation (Fig. 5 D) is very
similar to the loadings for PC2, which demonstrates that this
principal component describes changes that occur throughout
the experiment, as described above, and not the appearance
of an additional intermediate state. The scores of this com-
ponent show a peak in the middle of the ramp phase (Fig.
5 A), indicating that the major change in the monomer/trimer
ratio occurs in this period during which the concentration of
free glucagon rapidly decreases because the free glucagon
attaches to fibrils. None of the higher principal components,
the total of which explains the remaining 0.7% of the varia-
tion, showed any systematic changes of the scores with time.
We therefore were unable to find evidence for any NMR-
observable intermediates other than the proposed monomer-
trimer free glucagon components observed with PCA.
Overall, this analysis led us to a model of nucleated growth
mechanism that is illustrated schematically in Fig. 6. With
respect to the nucleated growth, it is compatible to a model
recently discussed by Collins et al. (55) in the context of prion
fibril formation. The nucleated growth model suggests that
there is a higher binding affinity of free molecules (trimers,
in the context of our study) of glucagon to already existing
fibrillar structures, rather than an affinity for mutual binding
that could result in the buildup of larger oligomers. There
are no larger intermediates detectable. On the side of the free
molecules, there is an exchange between monomers and
trimers. Only the trimers allow binding to a fibril, which is
possibly due to an advantageous structure. This model does
not demonstrate whether the whole trimer binds or whether
FIGURE 5 PCA of the spectra series in Fig. 2 A. (A) Scores of the
principal components PC1 (black) and PC2 (gray) as a function of exper-
iment time. (B and C) Loadings of PC1 (B) and PC2 (C). (D) Weighted
difference between spectra acquired at the beginning and the end of the
experiment (end to beginning). The scores are scaled so that the relative
variance of the scores reflects the relative variance in the PCs. The insets in B
and C show blowups of the loadings corresponding to the amide protons of
Ser-2 and Gln-3.
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it only facilitates the binding of one molecule. Furthermore,
the model suggests a certain probability of fibril fragmenta-
tion of fibrils.
In the following section, aspects of fibril formation will be
discussed on the submolecular level.
Secondary structure
The folding/unfolding and structural rearrangement pro-
cesses during fibril formation are an intensely debated topic
in the literature (1). This debate involves discussion of
structural features with the highest propensity for fibril for-
mation (59) and exposure of these features during ‘‘prefibril’’
structural rearrangements, and so on. To gain further insight
into the secondary structure of free glucagon molecules in the
initial phase of the aggregation, we identified medium-range
crosspeaks of a NOESY spectrum of a fresh sample of 7.0-
mg/mL concentration. There is a large number of crosspeaks
between residues i and i1 3 or i1 4 for the residues ranging
from Ser-9 until the C-terminus, as illustrated in the diagram
in Fig. 7, along with secondary structure, hydrophobicity,
charge, and fibril formation predictions, all of which are
residue-specific characteristics commonly discussed in rela-
tion to fibril formation. The long-range NOE crosspeak pat-
tern provides strong evidence for a stable a-helical structure
as supported by the secondary structure prediction. This is
consistent with the crystal structure (45) showing an a-helical
structure in this part of the molecule. By definition, amyloid
fibrils, however, are aggregates with a typical b-strand struc-
ture. The question, then, arises: at what stage is the b-strand
structure established, if glucagon is mainly a-helical?
In addition to NOE crosspeak signatures, NMR provides
further possibilities to determine the secondary structure,
which may be easier to quantify throughout the fibril for-
mation process. The easiest evidence can be obtained from
the chemical shift of the Ha protons (60), and the J coupling
between HN and Ha, which reflects the dihedral angle f (61).
Fig. 8 A shows the secondary chemical shift, i.e., the devia-
tion from the amino acid–specific random coil average (62),
for the Ha resonances that could be resolved in a
1H-TOCSY
experiment for a fresh sample at 1.4 mg/mL glucagon. Fig.
8 B shows the corresponding 3J(HN,Ha) coupling constants.
Both are clearly indicative of an a-helical structure for the
bulk of the dilute sample, whereas the N-terminus in partic-
ular gives—like in the NOESY crosspeak pattern—no con-
sistent helical structure. It should be noted that only a
consistent secondary shift of several residues of .0.1 ppm
can be interpreted as evidence for a secondary structure.
To identify changes in the secondary structure of the
‘‘liquid-state NMR observable’’ parts of the glucagon sample
upon fibril formation, an excerpt of the fingerprint region of a
NOESY spectrum of a 7.0-mg/mL sample as a function of
time during aging was examined (Fig. 9). Again, there was no
sign of additional peaks stemming from another conforma-
tion building up during this period of measurement; the same
observation applied to the corresponding TOCSY spectrum.
A potential change in conformation could be observed only
by a gradual shift of the peaks, representing the average of
two (or more) conformations. Generally, the shifts of the
peak positions become more pronounced for the residues
from Thr-7 onward than for the N-terminus, and they are
more pronounced for the HN proton than for the Ha proton.
Due to spectral overlap, the time variation of the Ha chemical
FIGURE 6 Model of a fibril aggregation pathway com-
patible with the sigmoidal decay and lack of evidence of
higher-order oligomers. Monomers and trimers coexist in
an equilibrium given by K. The data show a sigmoidal
decay during fibril formation (Fig. 3), which indicates a
preferential binding of molecules to existing fibrils (nucle-
ated growth). Only the trimers add to existing fibrils with
the rate r, as concluded from the asymmetry of the decay
curve (Fig. 3 D). There is no measurable off-rate from the
fibrils, as the signal intensity approaches asymptotically
zero (Fig. 3 C).
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shift could be extracted only for nine residues, three of which
are shown in Fig. 8 C. Except for Gln-20, there are no sig-
nificant changes that could indicate changes toward a
b-strand conformation for the observable part of the sample.
This result supports the model in which free glucagon atta-
ches directly to bigger aggregates, the size of which imme-
diately renders them undetectable by liquid-state NMR.
There is no evidence of a degenerative misfolding of mon-
omers preceding fibril formation, as discussed in the context
of various fibril-forming systems (1). Note, however, that
many of these fibril-forming systems, in contrast to gluca-
gon, are globular proteins of at least 100 residues with
well-defined tertiary structures. Our findings indicate that the
a-helical structure in the C-terminal part of the molecule is
preserved through the initial phases of fibril formation and
that the conversion from a-helical secondary structure to
b-strands occurs, at the earliest, upon or after attachment of
the free glucagon to the fibril aggregate. At that point, it is no
longer visible by liquid-state NMR. This interpretation
leaves unanswered the question of how the free glucagon
binds to the aggregate while remaining mainly in an a-helical
conformation. The following deuterium exchange experi-
ment could provide an answer.
FIGURE 7 Medium-range NOEs of glucagon
in comparison with the secondary structure pre-
diction (70), hydrophobicity (71), charge, and ag-
gregation propensity according to TANGO
prediction (67). Secondary structure labels: helix
(H); coil (C, all other than a-helix or b-strand);
dashes represent no sufficiently reliable predic-
tion. Hydrophobicity: .0.8 (black), 0.2– 0.65
(gray), and ,0.4 (white). Charge at pH 2: 12
(black), 11 (gray), and 0 (white).
FIGURE 8 (A) Secondary chemical shift, as the difference of the fre-
quency of the Ha proton to the random coil average value for the amino acid
type, for 7.0 mg/mL glucagon. (B) J coupling between amide and a-proton.
Dashed lines show the generally accepted limits for the different secondary
structure elements in A and B. (C) Development of the secondary chemical
shift of the observed signals over the ramp phase of fibril formation. Ser-8
(dots), Leu-14 (triangles), and Gln-20 (squares).
FIGURE 9 Excerpts of a series of NOESY spectra acquired subsequently
during the ramp phase of glucagon fibril formation. Brown contour lines
represent 30 min–4 h 30 min after preparation of a 7.0-mg/mL sample, His-1
e1 peak intensity in a 1D reference spectrum acquired before the NOESY
spectra: 100%. Red represents 4 h 45 min – 8 h 45 min (70%). Green
represents 9–13 h (25%). Blue represents 13 h 15 min – 17 h 15 min (15%).
The scaling was adjusted to compensate for the different polarization loss
during the 2D pulse sequence due to faster relaxation in the first spectra. The
relative scales of the lowest contour line are 0.4 (brown); 0.5 (red); 0.85
(green); and 1.0 (blue).
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Deuterium exchange
To identify the parts of the glucagon molecule that participate
in the formation of fibrils and the parts that may be more
flexible and accessible to the surrounding water phase, we
subjected mature fibrils to hydrogen/deuterium exchange of
amide hydrogens over 24 h. For subsequent liquid-state
NMR analysis, the fibrils were dissolved in trifluoroacetic
acid to form free glucagon and solubilized in DMSO (63)
while preserving the attained protection pattern. This process
has been described previously in the contexts of HET-S,
b2-microglobulin, and PrP (23,49,64). The
1H-NMR spectra
then will reveal higher residual intensity (or lower signal loss)
for amide hydrogens of residues buried in the fibril and so, to
a lesser extent, substituted by deuterium. The exchange data
in Fig. 10 show that the flexible N-terminus has retained the
most signal intensity, thus displaying the best protection to-
ward deuterium exchange. In this region, the amide groups
have preserved their hydrogen to.20% on average, whereas
the remainder of the peptide only has ;10% hydrogen re-
maining. A plausible explanation for this finding could be
that the nonstructured N-terminus forms the b-stranded core
of the fibrils, as illustrated schematically in Fig. 11. This
conclusion would support a model in which only a fraction of
the peptide is responsible for fibril formation, whereas the
remainder of the peptide is packed without intermolecular
bonds (and potentially with preserved a-helical structure as
shown in Fig. 11), which has been discussed previously in the
context of several other fibril-forming proteins (1). With spe-
cific attention to the N-terminus, it is interesting to note that the
highly charged histidine is believed to play a role in the fibril
formation process in several cases (65,66), and the first amino
acid of the N-terminus of glucagon is a histidine. The model in
Fig. 11 contradicts the likelihood of building intermolecular
bindings to initiate aggregation as predicted by the software
TANGO (http://tango.crg.es/) (67). As shown in Fig. 7, the
TANGO algorithm gives the highest scores to a part close to
the C-terminus, where glucagon has a hydrophobic patch
without charged residues. This region forms the intermolec-
ular binding site in the trimer crystal structure (45). Pedersen
et al. (68) also found that the TANGO predictions are not
fully consistent with the effects of mutations in the glucagon
sequence in relation to fibril formation. Indeed, they observed
that both N- and C-terminal residues are involved in the fibril
formation process (68). This is also supported by the pre-
dictions of a more recent algorithm, the prediction of amyloid
structure aggregation or PASTA (http://protein.cribi.unipd.it/
pasta/) (69), which shows a propensity for the formation of
anti-parallelb-strands between residues 2–10 (C.B. Andersen,
Novo Nordisk, personal communication, 2007).
The hypothetical model in Fig. 11 offers an alternative or
additional explanation as to why we did not detect any signs
of a conformational change away from the a-helical structure
for the major part of glucagon, neither through secondary
chemical shifts nor reduction of the corresponding NOEs. In
this model, the a-helix does not contribute to intermolecular
binding and remains preserved, at least during the very early
stage of aggregation. We emphasize that the NMR data do
not exclude that the helix is unraveled and so subject to a
transition to a b-sheet conformation after the attachment of
glucagon to a fibrillar nucleus. The hypothesis, however,
would provide an answer to the obvious question of how a
peptide of predominant and stable helical structure can form
b-stranded fibrils.
CONCLUSIONS
Based on liquid-state NMR experiments, this work sets up
hypotheses for the formation of fibrils by the example of the
peptide hormone glucagon in terms of pathways, kinetics,
and the fibril core. Except for signals from a concentration-
dependent monomer-trimer equilibrium, there are no signals
of intermediate oligomer states visible by liquid-state NMR
during fibril formation of glucagon. The sigmoidal kinetics of
fibril formation, which is observable by the decay of peak in-
tensities, indicates a process whereby free glucagonmolecules
FIGURE 10 Exchange of amide protons with deuterium in glucagon
fibrils. The higher the residual signal, the less accessible the amide proton is.
FIGURE 11 Hypothetical model of glucagon aggregation to fibrils com-
patible with the H/D exchange experiment in conjunction with the 1H liquid-
state NMR information on free glucagon. The N-termini form the core of the
fibrils (presumably in the form of b-strands, as indicated by strong partic-
ipation in amide hydrogen-bonding, but not revealed in terms of secondary
structure from our NMR experiments). The orientation could also be
parallel.
Glucagon Fibril Formation by Liquid NMR 375
Biophysical Journal 95(1) 366–377
bind directly to bigger aggregates rather than to other free
molecules. Most interestingly, our observations are compati-
ble with a model in which the fibril-forming species is the
trimer. From liquid-state NMR data, we do not observe any
sign of conversion from a-helix to b-strand conformation
before binding to bigger aggregates. There is an indication that
the N-terminus, which has no distinct secondary structure in
free glucagon, forms intermolecular b-strands and thus builds
the core of the fibrils. Because of the absence of intermediate
states in size and concentration allowing detection by liquid-
state NMR, solid-state NMR spectroscopy on isotope-labeled
samples would be a natural next step for a more detailed
structural analysis of glucagon fibrils on an atomic level.
Furthermore, the obvious importance of the trimer implies the
question whether its structure in solution complies with its
triangular crystal structure.
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